 |
|
|
| |
Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon alpha-2a and Ribavirin in the PILLAR Study
|
| |
| |
Reported by Jules Levin
EASL 2011 Berlin March 30-April 3
Jeroen AERSSENS,1 Greg FANNING,2 Annick SCHOLLIERS,3
Oliver LENZ,4 Monika PEETERS,5 Goedele DE SMEDT,6
Michael W FRIED7
1Department of Translational Genomics & Genetics; 2Department of Infectious Disease and Vaccines; 3Department of Enabling Biology; 4Department of Clinical Virology; 5Department of Statistics; 6Department of Clinical Development, Tibotec, Beerse, Belgium; 7University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
|
| |
|
|
|
|
|
